Gedeon Richter - Instant Earnings Comment
Rating: Accumulate (unch.)
Target price (12-month): HUF 6,320 (unch.)
Current share price: HUF 5,735
Key points for Q4/18 results:
- Total revenues were HUF 121.6 bn (+10% YoY ) higher than cons. estimate of HUF 111.9 bn and our estimate of HUF 110.5 bn.
- Reported EBIT amounted HUF -7.6 bn (vs. HUF -32.9 bn in Q4/17) including completely unexpected impariment losses of HUF 24.3 bn related to Esmya. Clean EBIT amounted to HUF 16.7 bn (+6% YoY). Consequently, clean EBIT margin came in at 13.7% in Q4/18 vs. 14.3% in Q4/17, and thus 90 bps below the median of analysts’ expectations of 14.6%.
- Clean operating results were down predominantly due to lower net sales, with lower Esmya sales and continued depreciation of the RUB against the HUF).
- Gross margin dropped to 53.2% from 55.8% YoY mainly due to higher low-margin Romanian wholesale revenue. Higher Vraylar sales (USD 27.3 mn vs. USD 15.3 mn in Q4/17), advancing Bemfola sales (EUR 11.3 mn vs. EUR 9.6 mn in Q4/17) proved helpful, however.
- OpEx after adjusted for one-off items rose 5% YoY due to higher crawl-back payments and wages.
- Reported net income came in at HUF -16.4 bn compared to HUF -35.7 bn in Q4/17. Clean net income was HUF 11 bn in line with market expectations and our estimate. The derecognition of deferred tax assets led a reduction in deferred tax assets.
Chemical Works of Richter Gedeon is a multinational pharmaceutical company that is engaged in the research, development, production and marketing and trade of pharmaceutical products. Co.'s activities are divided into two major business segments: Pharmaceutical, including research, development and manufacturing of pharmaceutical products; and Wholesale and Retail including wholesale and retail trade through the distribution chain as well as marketing of its products. Co. is primarily engaged in production of gynecological, cardiovascular and gastroenterological products, antibiotics, antimicotics, OTC and medicines for treatment of the central nervous system.
Concorde Securities Ltd. is Hungary’s leading independent company engaged in investment banking activities. It provides its clients with integrated financial services, including securities trading, research, corporate financing advisory, capital market transactions, wealth management and investment advisory. The operational management of the company is the responsibility of the CEO, while the owners/managers (who control one-third of the company through their shares and options) are in charge of its strategic governance. Concorde Securities Ltd. is a member of the Budapest, Frankfurt, Warsaw and Bucharest stock exchanges, as well as of the Hungarian Association of Investment Service Providers.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.